Logo
    Home > Topics > ebgi

    ebgi

    Explore "ebgi" with insightful episodes like "Making Bowel Preparation Palatable: Efficacy of a Novel Sports Drink Flavor-Optimized PEG and Sulfate Bowel Preparation", "Add Prophylactic Pancreatic Duct Stents to Rectal Indomethacin to Minimize Post-ERCP Pancreatitis in High-Risk Patients", "Continued Treatment With Tirzepatide Is Necessary to Maintain Weight Loss", "Non-Erosive GERD Does Not Lead to an Increased Risk of Esophageal Adenocarcinoma" and "Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment?" from podcasts like ""Evidence-Based GI: An ACG Publication and Podcast", "Evidence-Based GI: An ACG Publication and Podcast", "Evidence-Based GI: An ACG Publication and Podcast", "Evidence-Based GI: An ACG Publication and Podcast" and "Evidence-Based GI: An ACG Publication and Podcast"" and more!

    Episodes (76)

    Making Bowel Preparation Palatable: Efficacy of a Novel Sports Drink Flavor-Optimized PEG and Sulfate Bowel Preparation

    Making Bowel Preparation Palatable: Efficacy of a Novel Sports Drink Flavor-Optimized PEG and Sulfate Bowel Preparation
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Ahmad Abu-Heija, MBBS discuss “Comparison of a novel, flavor-optimized, polyethylene glycol and sulfate bowel preparation with oral sulfate solution in adults undergoing colonoscopy,” by Summarizing Bhandari R, Goldstein M, Mishkin DS, et al. J Clin Gastroenterol; 2023;57(9):920-927.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usFebruary 21, 2024
    colonoscopy
    endoscopy
    ebgi
    bowel prep

    Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment?

    Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment?
    Philip Schoenfeld, MD, MSEd, MSc and Bharati Kochar, MD, MS discuss “Early Ileocecal Resection for Crohn’s Disease is Associated with Improved Long-Term Outcomes Compared with Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study,” by Agrawal M, Ebert AC, Poulsen G, et al. Gastroenterology 2023; 165:976-985.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usJanuary 17, 2024
    ibd
    crohns
    ebgi
    ileocecal

    Post-Colonoscopy Colorectal Cancer Due to Missed Polyps in Proximal Colon or Rectum with Sub-Optimal Bowel Cleansing

    Post-Colonoscopy Colorectal Cancer Due to Missed Polyps in Proximal Colon or Rectum with Sub-Optimal Bowel Cleansing
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jeffrey Lee, MD, MPH discuss “Root-cause Analysis of 762 Danish Post-colonoscopy Colorectal Cancer Patients,” by Troelsen FS, Sørensen HT, Pedersen L, Brix LD, Grode LB, Dekker E, Erichsen R. Clin Gastroenterol Hepatol. 2023 Nov;21(12):3160-3169.e5. Epub 2023 Apr 7.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usJanuary 17, 2024
    colonoscopy
    colon
    ebgi
    polyps
    pccrc

    Hepatocellular Carcinoma Incidence Rates Are 2%-3% in US Patients with Cirrhosis Regardless of Etiology

    Hepatocellular Carcinoma Incidence Rates Are 2%-3% in US Patients with Cirrhosis Regardless of Etiology
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Nicole Rich, MD, MSCS discuss “Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) study,” by Reddy KR, McLerran D, Marsh T et al. Gastroenterology 2023; 165(4): 1053-1063.e6.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usDecember 13, 2023
    cirrhosis
    carcinoma
    ebgi
    hepatocellular

    ICYMI: Lynch Syndrome-An Aspirin a Day Keeps Colorectal Cancer Away!

    ICYMI: Lynch Syndrome-An Aspirin a Day Keeps Colorectal Cancer Away!
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swati Patel, MD, MS discuss “Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial,” by Burn J, Sheth H, Elliot F, et al. Lancet 2020;395:1855-63.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usDecember 13, 2023
    cancer
    colon
    aspirin
    crc
    ebgi

    Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTIS

    Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTIS
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” by Ford AC, Wright-Hughes A, Alderson S, et al. Lancet 2023; 402: 1773-85.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usDecember 13, 2023
    ibs
    antidepressants
    tricylic
    amiytriptyline
    ebgi

    Post-Endoscopy Esophageal Adenocarcinoma: Take a PEEC at Endoscopy Quality in Barrett's Esophagus

    Post-Endoscopy Esophageal Adenocarcinoma: Take a PEEC at Endoscopy Quality in Barrett's Esophagus
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jennifer Kolb, MD, MPH discuss “Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study,” by Wani S, Holmberg D, Santonin G, et al. Gastroenterology 2023; 165:909-19.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usNovember 15, 2023
    esophagus
    adenocarcinoma
    ebgi
    barretts

    Etrasimod, a Sphingosine 1-Phosphate Receptor Modulator, for Moderate-Severe Ulcerative Colitis: New Options for Oral Therapy

    Etrasimod, a Sphingosine 1-Phosphate Receptor Modulator, for Moderate-Severe Ulcerative Colitis: New Options for Oral Therapy
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MS discuss “Etrasimod as Induction and Maintenance Therapy for Ulcerative Colitis (ELEVATE): Two Randomised, Double-Blind, Placebo-Controlled, Phase 3 Studies,” by Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Lancet 2023; 401: 1159-71.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usNovember 15, 2023
    colitis
    etrasimod
    ebgi

    The New Frontier of Combination Therapy for IBD: The VEGA RCT

    The New Frontier of Combination Therapy for IBD: The VEGA RCT
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial,” by Feagan BG, Sands BE, Sandborn WJ, et al. Lancet Gastroenterol Hepatol. 2023; 8: 307-20.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usOctober 18, 2023
    vega
    colitis
    ebgi

    ICYMI: Biosimilar BI 695501 Has Similar Safety and Efficacy to Adalimumab for the Treatment of Crohn’s Disease: VOLTAIRE-CD Study

    ICYMI: Biosimilar BI 695501 Has Similar Safety and Efficacy to Adalimumab for the Treatment of Crohn’s Disease: VOLTAIRE-CD Study
    Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial,” by Hanauer S, Liedert B, Balser S, et al. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):816-825. Epub 2021 Aug 11.
    Evidence-Based GI: An ACG Publication and Podcast
    en-usOctober 18, 2023
    colitis
    biosimilar
    ebgi
    adalimumab
    Logo

    © 2024 Podcastworld. All rights reserved

    TwitterYouTubeInstagramPinterestFacebookLinkedIn

    Pages

    PodcastsEpisodesTopics

    Support

    Refund PolicyTerms of ServiceContact usPrivacy Policy

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io